Relay Therapeutics (RLAY) stock plummeted 13.33% during the pre-market trading session on Thursday, following the company's disappointing earnings report for the fourth quarter of 2024.
While Relay Therapeutics reported better-than-expected earnings per share (EPS) of -$0.45, beating analyst estimates of -$0.56, the company failed to generate any revenue during the quarter. This missed analysts' expectations of $6.08 million in revenue, weighing heavily on the stock's performance.
Additionally, Relay Therapeutics reported a quarterly loss of $76 million, further contributing to the stock's decline. As a biotech company without any current products on the market, missed revenue expectations and continued losses can be seen as concerning by investors, as it raises questions about the company's ability to generate profitable growth in the future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。